PLOS: DNA Science

OCTOBER 12, 2023

Can they deliver healing genes without triggering an overactive immune response? The details are disturbingly reminiscent of the famous case of Jesse Gelsinger , who died from a ferocious immune response to experimental gene therapy in September 1999. million DNA bases. Muscles stop working.

Therapies 69

Therapies Immune Response DNA Virus 69

PLOS: DNA Science

OCTOBER 19, 2023

Last week DNA Science covered a setback in a clinical trial of a gene therapy for Duchenne muscular dystrophy (DMD). It aims to correct the faulty instructions at the DNA level, straightforward, at least conceptually, because mutations are deletions, of part or all of the gene. That’s not the case for ALS.

Therapies 111

Therapies FDA Clinical Trials DNA 111

Drug Target Review

OCTOBER 4, 2023

2 In response, DNA-damaging agents that could target the entire cell cycle received renewed attention as ADC payloads. More recently, researchers have begun to look at conjugating immunomodulatory agents to antibodies to directly activate an immune response against the tumour. Science 261 , 212–215 (1993).

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

Broad Institute

AUGUST 7, 2023

Related people Paul Blainey Nir Hacohen A signaling protein known as STING is a critical player in the human immune system, detecting signs of danger within cells and then activating a variety of defense mechanisms. Paper Cited Liu B, Carlson R, et al. Human STING is a proton channel. Online August 3, 2023. DOI :10.1126/science.adf8974.

Regulations 91

Regulations Clinical Trials Engineering DNA 91

Drug Target Review

APRIL 3, 2024

Everything started in school with an experiment on isolating DNA from bananas. Making a little tangle of DNA visible to the eye and understanding that this is the basis of complex organisms, which might be altered in disease, was the defining moment for my future path in life sciences.

Science 105

Science Clinical Development Treatment DNA 105

Drug Target Review

MAY 14, 2024

Since cancer cells are under chronic stimulation of ER stress, the polypeptides cannot activate innate immune sensors in cancer cells even upon the polypeptide treatment. Which natural agonists impede the activation of intracellular DNA sensors in APCs, and what challenges do they pose?

Engineering 59

Engineering Immune Response FDA Approval Clinical Trials 59

The Pharma Data

DECEMBER 23, 2020

” Dr. Stanley Plotkin , Professor Emeritus at The Wistar Institute, said, “INOVIO’s DNA vaccine appeared to be quite safe with few significant reactions but yet induced both antibody and T cell responses to SARS-CoV-2.” About INOVIO’s DNA Medicines Platform. mg and 2.0

DNA 40

DNA Vaccine Clinical Trials Immune Response 40

PLOS: DNA Science

OCTOBER 3, 2024

The idea to redirect an immune response against a pathogen to fight cancer goes back to 1891, when Manhattan bone surgeon William Coley became intrigued by a man’s neck tumor that melted away after he contracted a nasty Streptococcus skin infection. Because research is very active in this field, William B. .’”

Vaccine 52

Vaccine Immune Response DNA Treatment 52

Drug Target Review

APRIL 26, 2023

Gene-editing methods allow researchers to modify DNA, resulting in alterations in physical characteristics such as eye colour and susceptibility to diseases. To achieve this, scientists utilise various technologies that function similarly to scissors, precisely cutting the DNA at a particular location.

RNA 98

RNA Medical Schools Engineering DNA 98

Drug Target Review

OCTOBER 26, 2023

Genome engineering and gene therapies that manipulate DNA sequences in cells have driven a biotechnological revolution over the past decade. 9 In addition, host immune responses further add to the complexity of developing cell-specific AAV capsids for clinical applications.

Engineering 105

Engineering Virus Therapies Immune Response 105

Codon

FEBRUARY 13, 2024

doi: 10.2210/rcsb_pdb/goodsell-gallery-048 The Virus that Cures It’s been over 25 years since the science magazine Discover first ran an extraordinary article about how a long-forgotten medical treatment, used in the former Soviet country of Georgia, could save us from the growing threat of untreatable, drug-resistant infections.

Therapies 117

Therapies DNA Virus Clinical Trials 117

Drug Target Review

NOVEMBER 6, 2023

For example, combining IO agents with ADCs to mount a two-pronged attack against cancer by activating an anti-cancer immune response and directly killing cancer cells may drive stronger and more durable responses in the clinic. References Blood Cancer UK.

Small Molecule 111

Small Molecule Therapies Treatment Disease 111

Drug Target Review

JUNE 9, 2023

An antigen is a protein that can induce an immune response in the body. While tumour cells share a majority of their DNA with healthy cells, they also carry numerous unique mutations. This first T-cell therapy product targets a common shared neoantigen found in patients with solid tumours.

Treatment 105

Treatment Packaging Clinical Research Therapies 105

Codon

SEPTEMBER 29, 2024

mRNA was the intermediate stage between DNA and protein, a dynamic entity that shifted depending on the second-to-second needs of the cell, able to point out if a cell was cancerous or stressed, what kind of cell it was, and so on. While mRNA data was often illuminating, their interpretation was tricky; more akin to art than science.

Engineering 132

Engineering Virus DNA Therapies 132

LifeSciVC

JULY 1, 2024

One thread that has run throughout it has been my passion for science as a lens for looking at the world. In particular, I love connecting science to daily life. Pfizer’s recent campaign around “ Science Will Win ” similarly appealed to the ethos of the power of science to help humanity. Remember life’s Central Dogma.

Science 80

Science Immune Response Molecular Biology RNA 80

Broad Institute

AUGUST 11, 2022

The study appears in Science. Microbial armory In an earlier study, the researchers scanned data on the DNA sequences of hundreds of thousands of bacteria and archaea, which revealed several thousand genes harboring signatures of microbial defense. Each of these viral proteins activated a different STAND ATPase to protect the cell.

DNA 52

DNA Virus Immune Response Bioinformatics 52

Codon

DECEMBER 12, 2024

” The report accompanies an article in Science , also released today, entitled “Confronting Risks of Mirror Life.” For the article in Science , more than 30 scientists from ten countries are calling on the broader community to confront the risks of mirrored life. ” But what, exactly, is a mirrored organism?

DNA 81

DNA RNA Vaccine Virus 81

Drug Target Review

SEPTEMBER 8, 2023

The study’s outcomes are also the fruit of a fruitful collaboration involving scientists from the RIKEN Center for Integrative Medical Sciences in Japan, alongside local research teams from UC San Diego and the Salk Institute. The cell’s nucleus, containing compacted DNA, is centrally positioned within the cell. .”

Regulations 98

Regulations Research DNA Immune Response 98

The Pharma Data

APRIL 8, 2021

Leadership in DNA damage response demonstrated in multiple presentations for AZD5305, a next-generation PARP1 selective inhibitor. Data for AZD5305 will demonstrate how the next wave of DNA damage response medicines can build on the success of PARP inhibitors, potentially allowing patients to stay on treatment longer.

DNA 52

DNA Immune Response Therapies Treatment 52

PLOS: DNA Science

JANUARY 4, 2024

.” CRISPRs are short DNA sequences, peppered with repeats, that latch onto DNA-cutting enzymes, commandeering and directing them to snip certain parts of a chromosome. The microbes deploy them to dismantle the genetic material of infecting viruses, a little like an immune response.

FDA Approval 52

FDA Approval DNA Therapies Clinical Trials 52

DrugBank

MAY 15, 2024

This method was more about serendipity than science. In the early 20th century, the discovery process was largely random , focused on cytotoxic agents that kill cells by disrupting key cellular functions like DNA replication. But as molecular biology has advanced, so too has our approach to finding new drugs.

Small Molecule 82

Small Molecule Molecular Biology Drugs Disease 82

PLOS: DNA Science

SEPTEMBER 5, 2024

This removes the cancer’s blocking of the immune response, so that T cells can fight the cancer. Keytruda’s classification based on mechanism, rather than its structure, is immune checkpoint inhibitor. Analyzing DNA patterns using AI may replace time-consuming process DNA and genomic sequencing tests, Yu said.

Treatment 52

Treatment FDA Approval DNA Small Molecule 52

The Pharma Data

MAY 15, 2023

Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera Gilead Sciences, Inc. Executive Vice President, Research, Gilead Sciences. About Gilead Sciences Gilead Sciences, Inc. The company was founded in 2021 by Stephen Kaldor, Ph.D., Qing Dong, Ph.D., and Gene Hung, M.D.,

Small Molecule 40

Small Molecule DNA Immune Response Science 40

Drug Target Review

JANUARY 9, 2024

Prior to the new study, the laboratories of Dr Michael Levin, Vannevar Bush Professor of Biology at Tufts University School of Arts & Sciences, and Dr Josh Bongard at the University of Vermont, created multicellular biological robots from frog embryo cells, named xenobots. This study was published in Advanced Science.

Laboratories 59

Laboratories Immune Response DNA Science 59

Drug Target Review

DECEMBER 5, 2024

2 Structure and function of AAV capsids in gene therapy Wild-type AAV is composed of a protein shell (capsid) that contains a single-stranded DNA genome encoding proteins involved in viral replication, structure and assembly. Therefore, vectors based on these serotypes may enable targeted gene delivery and optimal transduction efficiency.

Therapies 52

Therapies Virus DNA Compliance 52

Codon

APRIL 30, 2023

Yeast die for two reasons: Either their nucleolus (where the DNA is kept) degrades and dies, or their mitochondria whimpers out and they stop making energy. Read more at Science. Science abstracts were pulled from five different medical journals and then fed into ChatGPT. kilobases” of DNA into a plant genome. (My

Vaccine 52

Vaccine DNA Engineering RNA 52

Codon

APRIL 30, 2023

Yeast die for two reasons: Either their nucleolus (where the DNA is kept) degrades and dies, or their mitochondria whimpers out and they stop making energy. Read more at Science. Science abstracts were pulled from five different medical journals and then fed into ChatGPT. kilobases” of DNA into a plant genome. (My

Vaccine 52

Vaccine DNA Engineering RNA 52

Codon

JULY 27, 2023

From an article in Science : “After 6 months, the most promising varieties had their lignin content reduced by 49.1% in Science. Their cone cells, which are responsible for color vision, don’t work like normal. Transcription factors are proteins that bind to DNA and control gene expression. From Sulis D.B.

Therapies 52

Therapies RNA DNA Engineering 52

Codon

JULY 27, 2023

From an article in Science : “After 6 months, the most promising varieties had their lignin content reduced by 49.1% in Science. Their cone cells, which are responsible for color vision, don’t work like normal. Transcription factors are proteins that bind to DNA and control gene expression. From Sulis D.B.

Therapies 52

Therapies RNA DNA Engineering 52

LifeSciVC

MARCH 1, 2023

By Jonathan Montagu, CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC The phrase ‘build it and they will come’ dates all the way back to the Old Testament, and in more recent times has been romanticized in movies like Field of Dreams , but the concept also holds true in many areas of science.

Small Molecule 52

Small Molecule Immune Response DNA Therapies 52

The Pharma Data

APRIL 7, 2023

Imfinzi Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour’s immune-evading tactics and releasing the inhibition of immune responses. The Company’s focus is on some of the most challenging cancers.

Trials 40

Trials DNA Treatment Therapies 40

Dark Matter Blog

JULY 16, 2021

As soon as I learned about DNA and RNA, I wanted to be a molecular biologist. Last stops at RNA My last roles in biotech were where my original passion began: DNA and RNA. Delivering the IFN-β gene into tumors caused cancer cell apoptosis and activated both innate and adaptive anti-tumor immune responses.

Small Molecule 52

Small Molecule RNA Clinical Trials DNA 52

Codon

APRIL 9, 2023

“Computer science is to biology what calculus is to physics.” Thousands of transcription factors — proteins that bind DNA and control gene expression — were studied in human cells. Read Basic Science *mRNA decoding in human is kinetically and structurally distinct from bacteria. Thank you for being here.

Therapies 52

Therapies RNA Engineering Vaccine 52

Drug Target Review

DECEMBER 13, 2024

Innovations in payload substances, such as topoisomerase inhibitors (topo-1i), and next-generation DNA- damaging agents to replace older, more toxic agents. Engineering sites on the antibody to enable specific and consistent attachment of the cytotoxic drug to achieve an optimal drug-to-antibody ratio (DAR).

Therapies 52

Therapies Treatment Clinical Trials Drugs 52

The Pharma Data

OCTOBER 14, 2020

(Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first participant was enrolled in the observational PRECISION study (TNX-C002), to examine the immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic. Ilya Trakht, Ph.D.,

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40

The Pharma Data

DECEMBER 20, 2020

Pfizer and BioNTech announced additional data on neutralizing antibody and T-cell responses from their Phase I/II trial of their COVID-19 vaccine conducted in Germany. AB Science SA reported promising data from its Phase IIb/III trial of masitinib in patients with confirmed mild to moderate Alzheimer’s disease.

Vaccine 52

Vaccine Trials Therapies Small Molecule 52

The Pharma Data

JUNE 30, 2021

Mismatch repair deficiency (dMMR) occurs when the proteins that repair mismatch errors in DNA replication are missing or non-functional, leading to microsatellite instability-high (MSI-H) tumors. Bristol Myers Squibb is inspired by a single vision — transforming patients’ lives through science. About Opdivo.

Treatment 52

Treatment Trials FDA Approval Disease 52